On the basis of evidence that resistance to vascular endothelial growth factor ( VEGF ) receptor inhibition is caused by hypoxia-driven residual VEGF and other proangiogenic factors , combinations of agents from these classes were hypothesized to improve treatment outcomes relative to single-agent VEGF pathway blockade .